Montreux Equity et al. in $97m round for GC Aesthetics

In addition to the equity investment, the $97m financing also includes a debt package provided by London-headquartered credit platform Hayfin Capital Management.

GC Aesthetics plans to use the proceeds from the funding to refinance its existing debt, develop its IDE study to obtain FDA approval for its breast implants in the US, invest in product innovation and expand its position in the global aesthetics industry.

Previous funding
Montreux invested $30m in GC Aesthetics in October 2010. Subsequently, the company secured a $60m funding round from a consortium of investors in February 2014. The transaction saw US-based investor OrbiMed contribute $40m, while the remaining $20m came from Montreux and Oyster.

More recently, the business raised €20m from Montreux, Oyster and Barry's Tea Holdings in July 2016.

Company
Established in 2007 and based in Dublin, GC Aesthetics develops and manufactures a range of proprietary aesthetic implants for breast augmentation and breast reconstructive surgery. The company markets its products under two brands, Nagor and Eurosilicone, and has a presence in 70 countries worldwide.

People
Hayfin Capital Management – Howard Rowe (managing director, head of healthcare).
GC Aesthetics – Carlos Reis Pinto (CEO).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Expansion
• UK / Ireland
• Healthcare
• Venture
• Ireland